No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
Authors
Keywords
-
Journal
EUROPEAN HEART JOURNAL
Volume 39, Issue 5, Pages 374-381
Publisher
Oxford University Press (OUP)
Online
2017-10-27
DOI
10.1093/eurheartj/ehx661
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors
- (2017) Abdur Rahman Khan et al. Circulation-Cardiovascular Quality and Outcomes
- Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol
- (2017) Robert P. Giugliano et al. JAMA Cardiology
- Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies)
- (2016) Tamio Teramoto et al. AMERICAN JOURNAL OF CARDIOLOGY
- Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
- (2016) Michel Farnier et al. ATHEROSCLEROSIS
- Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
- (2016) Henry N. Ginsberg et al. CARDIOVASCULAR DRUGS AND THERAPY
- Interpretation of the evidence for the efficacy and safety of statin therapy
- (2016) Rory Collins et al. LANCET
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
- (2015) Dean J. Kereiakes et al. AMERICAN HEART JOURNAL
- PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N-of-1 Trials
- (2015) Kristopher J. Swiger et al. DRUG SAFETY
- The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
- (2015) Michael J. Lipinski et al. EUROPEAN HEART JOURNAL
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
- (2015) Christopher P. Cannon et al. EUROPEAN HEART JOURNAL
- Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
- (2015) Harold Bays et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
- (2015) Patrick M. Moriarty et al. Journal of Clinical Lipidology
- Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2015) Brian R. Ott et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (
- (2014) Brendan M. Everett et al. AMERICAN JOURNAL OF CARDIOLOGY
- Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial
- (2014) Eli M. Roth et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Statins and Cognitive Function
- (2013) Karl Richardson et al. ANNALS OF INTERNAL MEDICINE
- Statins and Cognition: A Systematic Review and Meta-analysis of Short- and Long-term Cognitive Effects
- (2013) Kristopher J. Swiger et al. MAYO CLINIC PROCEEDINGS
- PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population
- (2012) Iris Postmus et al. JOURNAL OF LIPID RESEARCH
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
- (2012) Evan A Stein et al. LANCET
- Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
- (2012) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low HDL Cholesterol Is a Risk Factor for Deficit and Decline in Memory in Midlife
- (2008) Archana Singh-Manoux et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- HDL: Close to Our Memories?
- (2008) Anatol Kontush et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now